Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose Escalation With Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMV564 Alone and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

NCT04128423 is registered in ClinicalTrials.gov with Amphivena Therapeutics, Inc. as lead sponsor.

NCT NCT04128423
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04128423 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose Escalation With Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMV564 Alone and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Lead sponsor
Amphivena Therapeutics, Inc.
Phase
Phase 1
Overall status
Unknown status
Start date
October 9, 2019
Completion date
December 31, 2021
Enrollment
65 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced or metastatic solid tumors